Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05154994
Title Tremelimumab, Durvalumab, and Belinostat for the Treatment of ARID1A Mutated Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah

transitional cell carcinoma


Belinostat + Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from for the field